Antibody Responses to Recombinant gp120, gp70 V1V2 Proteins and Cyclic V2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens

被引：0
|
作者：
Karasavvas, N. [1 ]
Karnasuta, C. [1 ]
de Souza, M. S. [2 ]
Madnote, S. [1 ]
Inthawong, D. [1 ]
Savadsuk, H. [1 ]
Rittiroongrad, S. [1 ]
Chantakulkij, S. [1 ]
Nitayaphan, S. [3 ]
Pitisuttithum, P. [4 ]
Thongcharoen, P. [5 ]
Siriyanon, V. [6 ]
Andrews, C. A. [7 ]
O'Connell, R. J. [7 ]
Michael, N. L. [7 ]
Ngauy, V. [1 ]
Kim, J. H. [7 ]
机构：
[1] USAMC AFRIMS, Bangkok, Thailand
[2] TRCARC, Southeast Asian Res Collaborat Univ Hawaii SEARCH, Bangkok, Thailand
[3] Royal Thai Army Armed Forces Res Inst Med Sci RTA, Bangkok, Thailand
[4] Mahidol Univ, Bangkok 10700, Thailand
[5] Mahidol Univ, Siriraj Hosp, Bangkok 10700, Thailand
[6] Chiang Mai Univ, Chiangmai, Thailand
[7] Walter Reed Army Inst Res, US Mil HIV Res Program MHRP, Silver Spring, MD USA
来源：
AIDS RESEARCH AND HUMAN RETROVIRUSES | 2013年 / 29卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：A50 / A50
页数：1
相关论文
共 50 条
  • [21] Inhibition of the anti-V3 loop response to a recombinant gp120SF2 vaccine by preexisting monoclonal antibody
    Keller, MA
    Arora, Y
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (09) : 855 - 860
  • [22] Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial
    Williams, W. B.
    Jones, K.
    Krambrink, A.
    Grove, D.
    Liu, P.
    Yates, N. L.
    Moody, M. A.
    Ferrari, G.
    Pollara, J.
    Moodie, Z.
    Morgan, C. A.
    Liao, H.
    Montefiori, D. C.
    Ochsenbauer, C.
    Kappes, J.
    Hammer, S.
    Mascola, J.
    Koup, R.
    Corey, L.
    Nabel, G.
    Gilbert, P.
    Churchyard, G.
    Keefer, M.
    Graham, B. S.
    Haynes, B. F.
    Tomaras, G. D.
    RETROVIROLOGY, 2012, 9
  • [23] Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial
    WB Williams
    K Jones
    A Krambrink
    D Grove
    P Liu
    NL Yates
    MA Moody
    G Ferrari
    J Pollara
    Z Moodie
    CA Morgan
    H Liao
    DC Montefiori
    C Ochsenbauer
    J Kappes
    S Hammer
    J Mascola
    R Koup
    L Corey
    G Nabel
    P Gilbert
    G Churchyard
    M Keefer
    BS Graham
    BF Haynes
    GD Tomaras
    Retrovirology, 9
  • [24] N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120
    Fischer, PB
    Karlsson, GB
    Butters, TD
    Dwek, RA
    Platt, FM
    JOURNAL OF VIROLOGY, 1996, 70 (10) : 7143 - 7152
  • [25] Early Vaccine-Induced V1V2 Antibody Responses in Four Pox-Protein Public Private Partnership (P5) HIV Vaccine Trials
    Laher, F.
    DiazGranados, C.
    Innes, C.
    Andersen-Nissen, E.
    Gray, G. E.
    Lu, H.
    Hutter, J.
    Mngadi, K.
    Marshall, K.
    Polakowski, L.
    Bekker, L. -G.
    Koutsoukos, M.
    Allen, M.
    Hosseinipour, M.
    Grunenburg, N.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24
  • [26] HIV-1 Env DNA prime plus gp120 and gp70-V1V2 boosts induce high level of V1V2-specific IgG and ADCC responses and low level of Env-specific IgA response: implication for improving RV144 vaccine regimen
    Wang, Qian
    Dai, Yanyan
    Sun, Zhiwu
    Su, Xiaojie
    Yu, Yufeng
    Hua, Chen
    Xu, Wei
    Jiang, Shibo
    Lu, Lu
    EMERGING MICROBES & INFECTIONS, 2017, 6
  • [27] Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
    Gottardo, Raphael
    Bailer, Robert T.
    Korber, Bette T.
    Gnanakaran, S.
    Phillips, Joshua
    Shen, Xiaoying
    Tomaras, Georgia D.
    Turk, Ellen
    Imholte, Gregory
    Eckler, Larry
    Wenschuh, Holger
    Zerweck, Johannes
    Greene, Kelli
    Gao, Hongmei
    Berman, Phillip W.
    Francis, Donald
    Sinangil, Faruk
    Lee, Carter
    Nitayaphan, Sorachai
    Rerks-Ngarm, Supachai
    Kaewkungwal, Jaranit
    Pitisuttithum, Punnee
    Tartaglia, James
    Robb, Merlin L.
    Michael, Nelson L.
    Kim, Jerome H.
    Zolla-Pazner, Susan
    Haynes, Barton F.
    Mascola, John R.
    Self, Steve
    Gilbert, Peter
    Montefiori, David C.
    PLOS ONE, 2013, 8 (09):
  • [28] The V1/V2 Loop Region of Simian-Human Immunodeficiency Virus Envelope gp120 is the Major Determinant of the Strain Specificity of the Neutralizing Antibody Response
    Laird, Melissa E.
    Igarashi, Tatsuhiko
    Martin, Malcolm A.
    Desrosiers, Ronald C.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 51 : 68 - 68
  • [29] A helical structure in the V2 domain of gp120 that localizes to the site of immune pressure in the RV144 vaccine trial is conserved in HIV and SIV envelopes
    Lertjuthaporn, S.
    Cicala, C.
    Van Ryk, D.
    Yolitz, J.
    Wei, D.
    Gorini, G.
    Franchini, G.
    Roederer, M.
    Mason, R.
    Pattanapanyasat, K.
    Kong, X. -P.
    Wibmer, K.
    Morris, L.
    Fauci, A. S.
    Arthos, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 20 - 20
  • [30] The Thai Phase Iii Clinical Trial (RV144) Induces the Generation of Antibodies That Target a Conserved Region Within the V2 Loop of GP120
    Karasavvas, N.
    Billings, E.
    Rao, M.
    Currier, J.
    Michael, N. L.
    Rerks-Ngarm, S.
    Pitisuttithum, P.
    Kaewkungwal, J.
    Ngauy, V.
    Nitayaphan, S.
    Madnote, S.
    Arworn, D.
    Kim, J.
    de Souza, M.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2011, 27 (10) : A29 - A29
12345